

# Abnormal Uterine Bleeding: A Management Algorithm

*John W. Ely, MD, MSPH, Colleen M. Kennedy, MD, MS, Elizabeth C. Clark, MD, MPH, and Noelle C. Bowdler, MD*

**Abnormal uterine bleeding is a common problem, and its management can be complex. Because of this complexity, concise guidelines have been difficult to develop. We constructed a concise but comprehensive algorithm for the management of abnormal uterine bleeding between menarche and menopause that was based on a systematic review of the literature as well as the actual management of patients seen in a gynecology clinic. We started by drafting an algorithm that was based on a MEDLINE search for relevant reviews and original research. We compared this algorithm to the actual care provided to a random sample of 100 women with abnormal bleeding who were seen in a university gynecology clinic. Discrepancies between the algorithm and actual care were discussed during audiotaped meetings among the 4 investigators (2 family physicians and 2 gynecologists). The audiotapes were used to revise the algorithm. After 3 iterations of this process (total of 300 patients), we agreed on a final algorithm that generally followed the practices we observed, while maintaining consistency with the evidence. In clinic, the gynecologists categorized the patient's bleeding pattern into 1 of 4 types: irregular bleeding, heavy but regular bleeding (menorrhagia), severe acute bleeding, and abnormal bleeding associated with a contraceptive method. Subsequent management involved both diagnostic and treatment interventions, which often occurred simultaneously. The algorithm in this article is designed to help primary care physicians manage abnormal uterine bleeding using strategies that are consistent with the evidence as well as the actual practice of gynecologists. (J Am Board Fam Med 2006;19:590–602.)**

Abnormal uterine bleeding is a common problem,<sup>1</sup> and its management can be complex.<sup>2,3</sup> Physicians are often unable to identify the cause of abnormal bleeding after a thorough history and physical examination.<sup>4,5</sup> The management of abnormal bleeding can involve many decisions about diagnosis and treatment,<sup>3,6,7</sup> which often occur simultaneously and without the benefit of comprehensive, evidence-based guidelines. The available evidence tends to focus on narrow treatment questions rather than the broad clinical approach to management.<sup>8,17</sup> It is not difficult to find long lists of

potential causes of abnormal bleeding, but primary care physicians need practical advice about how to approach this common problem.

Abnormal uterine bleeding includes both dysfunctional uterine bleeding and bleeding from structural causes. Dysfunctional bleeding can be anovulatory, which is characterized by irregular unpredictable bleeding, or ovulatory, which is characterized by heavy but regular periods (ie, menorrhagia).<sup>2</sup> Structural causes include fibroids, polyps, endometrial carcinoma, and pregnancy complications. Abnormal bleeding can also result from contraceptive methods.

Many articles have reviewed the management of abnormal uterine bleeding,<sup>3,6,7,15,16,18,21</sup> and they often include management algorithms. Although clinical algorithms have potential shortcomings,<sup>22,25</sup> there are data to support their benefit to both physicians and patients.<sup>26,29</sup> Rather than simply listing causes of abnormal bleeding, management algorithms force authors to face the same decisions clinicians face. Most algorithms simply


This article was externally peer-reviewed.

Submitted 24 April 2006; revised 10 August 2006; accepted 24 August 2006.

From the Department of Family Medicine (JWE, ECC), and Department of Obstetrics and Gynecology (CMK, NCB), University of Iowa Carver College of Medicine, Iowa City, IA.

*Conflict of interest:* none declared.

*Corresponding author:* John W. Ely, MD, MSPH, University of Iowa College of Medicine, Department of Family Medicine, 200 Hawkins Drive, 01291-D PFP, Iowa City, IA 52242 (E-mail: john-ely@uiowa.edu).



**Figure 1. Abnormal Uterine Bleeding between Menarche and Menopause.**

state the author's opinion about what to do. A MEDLINE search (1985 to present) found 76 review articles on abnormal uterine bleeding that appeared to address the topic comprehensively, and 24 of these included an algorithm. Of these 24 algorithms, 23 were based on the opinions of the authors and one was based on the available evidence.<sup>15</sup> This single evidence-based algorithm addressed only one aspect of abnormal bleeding (menorrhagia), and most of the diagnostic recommendations were based on grade C evidence (expert opinion). Authors who study clinical algorithms recommend validating them to assure their feasibility in practice,<sup>30,32</sup> but this is rarely done.<sup>27</sup> None of the 24 identified algorithms were systematically compared with actual practice. Our goal was to produce a comprehensive algorithm for the management of abnormal uterine bleeding that was consistent with the evidence and feasible in practice.

## Bleeding Patterns


We addressed abnormal uterine bleeding between menarche and menopause. We excluded premenarchal bleeding because of its rarity. We excluded amenorrhea and postmenopausal bleeding because

their generally straightforward evaluation has been well described elsewhere.<sup>3,4,33,34</sup> Postoperative, postpartum, and pregnancy-related bleeding were also excluded.

We found that gynecologists usually start the evaluation by determining the general pattern of abnormal bleeding (Figure 1). Thus, the algorithm starts by asking the physician to categorize patients according to the bleeding patterns defined in Table 1. Subsequent figures present algorithms for each pattern. The physician may have difficulty distinguishing prolonged periods from irregular bleeding, and we set an arbitrary bleeding duration of 12 days as a limit for menorrhagia. The distinction is

**Table 1. Bleeding Patterns**

<b>Normal:</b> The normal interval is 21 to 35 days. The normal duration of bleeding is 1 to 7 days. The amount should be less than 1 pad or tampon per 3-hour period
<b>Severe acute bleeding:</b> Bleeding that requires more than one pad/tampon per hour or vital signs indicating hypovolemia.
<b>Irregular bleeding:</b> Includes metrorrhagia, menometrorrhagia, oligomenorrhea, prolonged bleeding, intermenstrual bleeding, or other irregular pattern.
<b>Menorrhagia:</b> Heavy but regular cyclic bleeding plus >7 days of bleeding or clots or iron deficiency anemia. Prolonged bleeding >12 days should be considered irregular regardless of cyclic pattern.



**Figure 2. Severe Acute Bleeding in the Nonpregnant Patient.**

important because endometrial sampling can often be avoided in patients with menorrhagia. However, the conservative approach would be to follow the irregular bleeding algorithm (Figure 3) in borderline cases because it calls for endometrial sampling in women at high risk for endometrial cancer.

### Severe Acute Bleeding


Severe acute uterine bleeding in the nonpregnant patient usually occurs in one of three settings: the adolescent with a coagulopathy (most commonly von Willebrand disease<sup>35,36</sup>), the adult with submucous fibroids, or the adult taking anticoagulants. Initial management is based on hemodynamic stability as outlined in Figure 2. The patient is given high-dose estrogen (orally or intravenously depending on bleeding severity) and then a tapering schedule of oral contraceptives. One common oral contraceptive regimen is ethinyl estradiol 30 µg/norgestrel 0.3 mg (eg, LoOval) 1 active pill 4 times daily for 4 days, followed by 3 times daily for 3 days, followed by 2 times daily for 2 days, followed by once daily for 3 weeks. The patient then stops the pill for 1 week and then cycles in the usual manner, 3 weeks on and 1 week off, for at least 3 months. Once the patient is clinically stable, an investigation into the cause of bleeding includes screening coagulation studies and possibly transvaginal ultrasound (TVUS). The ultrasound may include a saline-infused sonohysterogram, especially when the endometrial stripe is thick, because

of the increased sensitivity for endometrial polyps and submucous fibroids.<sup>37,38</sup> In general, ultrasound is less likely to be helpful at menarche, and instead the evaluation for coagulopathy, especially von Willebrand disease, becomes more relevant.

### Irregular Bleeding

Irregular bleeding is a heterogeneous category that includes metrorrhagia, menometrorrhagia, oligomenorrhea, prolonged bleeding that can last weeks or months, and other irregular patterns. These patterns were lumped together in the algorithm because their initial management is similar.

Patients with *minor variations* of normal bleeding may not require the evaluation outlined in Figure 3. For example, irregular bleeding within 2 years of menarche is usually due to anovulation, secondary to an immature hypothalamic-pituitary-ovarian axis.<sup>21,39,40</sup> However, adolescents may request more than simple reassurance and can be offered oral contraceptives or a progestin as described in the algorithm (Figure 3). Missed periods and prolonged intervals are expected in perimenopause.<sup>41,42</sup> Intervals may also decrease in the perimenopause, but repeated intervals less than 21 days or other irregular patterns require endometrial sampling. In any reproductive-aged woman, a few days of premenstrual spotting, if it is contiguous with the period, can be a normal variant, but the total duration should be less than 8 days.<sup>43</sup> A few days of postmenstrual spotting, if it is contiguous



**Figure 3. Irregular Bleeding in the Nonpregnant Patient.**

with the period, can also be considered a normal variant.<sup>43</sup> Postmenstrual spotting is sometimes caused by endometritis, which can be treated with 100 mg of doxycycline twice daily for 10 days. Brief midcycle spotting can occur at the time of ovulation due to the normal dip in serum estrogen levels.<sup>43</sup> However, this is not common and should prompt an endometrial biopsy in women >35 years old.<sup>2</sup> A single early period (<21 days) may not require an endometrial biopsy even in a woman over age 35 if subsequent periods are regular and no other abnormal bleeding occurs. Early periods and occasional missed periods are common in younger women and may result from mental stress or illness.<sup>44,45</sup>

Before beginning hormonal therapy, *systemic causes* of abnormal uterine bleeding should be considered:

- If the uterus is tender, indicating possible chronic endometritis, the patient should be tested for gonorrhea and chlamydia and initially treated with 100 mg of doxycycline twice daily for 10 days, pending culture results.<sup>46,47</sup>
- Medications that can cause abnormal uterine

bleeding include phenytoin, antipsychotics (eg, olanzapine, risperidone), tricyclic antidepressants (eg, amitriptyline, nortriptylene), and corticosteroids (eg, prednisone, dexamethasone).<sup>48</sup>

- Abnormal uterine bleeding can result from advanced systemic disease such as liver failure or kidney failure.<sup>48</sup> However, laboratory screening for these diseases in the absence of obvious clinical findings is not necessary because abnormal bleeding is a late manifestation. The exception is thyroid disease (hypothyroidism or hyperthyroidism), which should be screened for early in the evaluation with a thyroid-stimulating hormone (TSH).
- Polycystic ovary syndrome (PCOS) is a common cause of abnormal uterine bleeding.<sup>49</sup> The diagnostic criteria for PCOS include at least two of the following<sup>50,51</sup>:
  1. Menstrual irregularity due to oligo- or anovulation.
  2. Signs of androgen excess, either on physical examination (eg, hirsutism, acne) or laboratory testing (eg, elevated testosterone).
  3. Evidence of polycystic ovaries by ultrasound.

In addition to these criteria, other causes of hyperandrogenism or abnormal bleeding must be excluded before making the diagnosis of PCOS. Conditions that should be ruled out include congenital adrenal hyperplasia (manifested by an elevated early morning 17-hydroxyprogesterone), androgen-secreting tumors (manifested by a serum testosterone >200 ng/dL or dehydroepiandrosterone sulfate >800 µg/dL), and hyperprolactinemia.

In women more than age 35 and those at risk for endometrial carcinoma (Figure 3), TVUS with or without a saline-infused sonohysterogram may be indicated before, after, or instead of endometrial biopsy. TVUS can detect endometrial polyps, uterine myomas, and endometrial hyperplasia.<sup>52,53</sup> Endometrial biopsy can detect hyperplasia, atypia, and carcinoma. The conservative approach is to do the endometrial biopsy whether or not a TVUS is obtained. However, other factors may enter this decision:

- TVUS may be indicated if the patient will likely require operative management (eg, office biopsy would be a technical challenge or fibroids suspected on physical examination or probable need for hysteroscopy or endometrial ablation).

- High-quality TVUS is not available in many locations. Also TVUS is costly and insurance status may influence the order of testing.
- One option is to first rule out neoplasia with the endometrial biopsy, then start hormonal therapy, and then obtain a TVUS only if abnormal bleeding persists despite hormonal therapy.
- TVUS is less invasive and less painful than endometrial biopsy. One study reported experience with initial TVUS and no further evaluation if the double-thickness endometrial stripe was <5 mm.<sup>54</sup> However, the conservative approach remains endometrial biopsy in women at risk for endometrial carcinoma.

### Menorrhagia

Menorrhagia is defined as blood loss greater than 80 mL per cycle. A more pragmatic but less precise definition is simply the patient's perception of excessive blood loss. Unfortunately, these judgments do not correlate well with actual blood loss.<sup>55</sup> Menorrhagia can often be managed without endometrial sampling because regular bleeding, even if heavy, is less concerning for endometrial cancer. However, if the bleeding is prolonged (>7 days) or does not respond to hormonal therapy as outlined




Figure 4. Menorrhagia in the Nonpregnant Patient.



**Table 2. Oral Contraceptive Pill****Combination Oral Contraceptive Pill**

If the goal is to achieve amenorrhea, the OCP can be given continuously, but is usually withdrawn every 3 to 4 months to allow endometrial shedding and avoid irregular bleeding.

**Irregular bleeding**

In most women, suspect a thin endometrium and cycle on OCP (eg, Necon 1/35) for at least 3 months. If PCOS is suspected (ie, thick endometrium), consider cyclic progestin (Table 3), and then continue cyclic progestin or switch to OCP.

If there is heavy bleeding at the time of the visit, start a moderate-estrogen OCP (eg, LoOval) one active pill QID  $\times$  4 days, then one TID  $\times$  3 days, then one BID  $\times$  2 days, then daily  $\times$  3 weeks, then skip 1 week, then cycle on OCP for at least 3 months.

**Menorrhagia**

Can start OCP any time but typically on Sunday following first day of menses.

**Contraindications to OCP**

Previous thromboembolic event or stroke

History of estrogen-dependent tumor

Active liver disease

Pregnancy

Hypertriglyceridemia

Older than 35 years and smokes  $>15$  cigarettes per day

Older than 40 years is not a contraindication but many physicians favor progestin for this age group.

in Figure 4, further evaluation with TVUS or endometrial sampling is indicated. Platelet function analysis to screen for von Willebrand disease should be ordered in women with severe menorrhagia or other signs of coagulopathy.<sup>36,56,58</sup> For treatment, women can be offered oral contraceptives if not contraindicated (Table 2), progestins (Table 3), nonsteroidal anti-inflammatory drugs, or observation. The decision between oral contraceptives and progestins is often based on contraindications to estrogen, most commonly smoking. A recent clinical trial found that the levonorgestrel intrauterine device (IUD) (Mirena) resulted in comparable quality of life scores and lower costs compared with hysterectomy in women with menorrhagia.<sup>59</sup> Women who prefer no hormones can be started on nonsteroidal anti-inflammatory drugs, which decrease blood loss.<sup>60,61</sup>

**Hormonal Contraception**

Breakthrough bleeding occurs commonly with low-dose oral contraceptive pills (Figure 5). If the abnormal bleeding persists after the first 3 months, a higher dose pill can be used, as indicated in Figure 5. Gonorrhea and chlamydia in association with

**Table 3. Progestin Therapy****Progestin therapy**

In most cases, use a cyclic progestin, usually medroxyprogesterone (Provera) because of its low cost. If PMS-like side effects are unacceptable, consider micronized progesterone (Prometrium), norethindrone (Aygestin), or megesterol (Megace).

**Cyclic progestins**

Start medroxyprogesterone 10 mg daily for 14 days, then off 14 days, then on 14 days, and so on without regard to bleeding pattern. If bleeding occurs before completing the 14-day course, the patient can double the dose (20 mg) and 'reset the clock' (count the first day of bleeding as day 1 and start medroxyprogesterone on day 14) or not reset the clock and continue the schedule without regard to bleeding pattern.

If the patient is bleeding at the time of the visit, start medroxyprogesterone 10 mg daily and increase every 2 days as needed to stop the bleeding (20 mg, 30 mg, 40 mg, 60 mg, 80 mg) until bleeding stops. However, the patient should be warned that intolerable PMS-like side effects may develop with high doses. Continue for 14 days and then cycle 14 days on, 14 days off, and so on.

**Continuous progestins**


Continuous progestins may be indicated if the goal is to achieve amenorrhea (eg, busy professional or athlete, intractable menstrual migraine, catamenial seizures, severe mental retardation). Maintaining amenorrhea is often more difficult than cycling a progestin (ie, there may be unpredictable spotting). Options include:

- Oral progestin: medroxyprogesterone Provera 10 to 20 mg daily or 'Minipill' (eg, 0.35 mg of norethindrone daily)
- Depo-medroxyprogesterone (Depo-Provera) 150 mg IM every 13 weeks. Often used in adolescents to improve compliance. Less often used in ages  $>40$  years due to risk of osteoporosis.
- Levonorgestrel IUD (Mirena).

oral contraceptives commonly leads to abnormal bleeding, and cervical cultures should be obtained.

Patients on depo-medroxyprogesterone with persistent irregular bleeding can be treated with a 7-day course of estrogen (eg, 1.25 mg of Premarin daily, 1 mg of estradiol daily, or an estrogen patch such as 0.1 mg Climara). This can be repeated if the abnormal bleeding recurs.

In patients with an IUD, abnormal bleeding may be associated with endometritis. After culturing the cervix, patients with a tender uterus can be treated with 100 mg of doxycycline twice daily for 10 days and possible removal of the IUD. In the absence of endometritis, patients with a copper IUD (Paragard) can be treated with one cycle of the oral contraceptive pill or 10 mg of medroxyprogesterone daily for 7 days. Patients with a progestin-releasing IUD (Mirena, Progestasert) can be treated with one cycle of the oral contraceptive pill. If the abnormal bleeding persists, the IUD can be removed and alternative contraceptive methods discussed.



**Figure 5. Oral Contraceptive Pill-associated Bleeding.**

### Comment

In this review, we developed an algorithm for the management of abnormal uterine bleeding and compared it to actual practice. The algorithm is generally consistent with previous comprehensive algorithms. For example, Albers and colleagues presented an algorithm that covered several pages in a recent review.<sup>3</sup> Space limitations forced the authors to use general recommendations such as “medical management” rather than specific drugs. Other algorithms have solved the space problem by limiting their algorithms to single aspects of abnormal bleeding, such as only menorrhagia<sup>15,62,63</sup> or only amenorrhea.<sup>64,67</sup> Some reviews start from the pathophysiologic perspective, addressing topics such as “anovulatory bleeding”<sup>2</sup> or “dysfunctional uterine bleeding,”<sup>68</sup> but this approach may be less helpful to clinicians because patients do not present with these labels.


Little is known about how to develop clinical algorithms. Authors recognize the importance of validating clinical algorithms, but they have little advice about how to do it or even what is meant by “validation.”<sup>30,31</sup> Validation could involve building algorithms that optimize patient preferences, physician preferences, compliance with the evidence,

conformity with physicians’ diagnostic reasoning processes, or, as in this study, conformity with actual practice. Algorithms could be tested by determining whether physicians follow the “correct” path (validity) and whether they follow the same path (reliability).

Although the algorithm presented in this article is based on the practice of gynecologists in a tertiary setting, the recommendations should be generally applicable to primary care settings in the United States because they consist of routine tests, such as pregnancy tests and endometrial biopsies, and simple treatments, such as oral contraceptives and progestins.

The algorithm is lengthy, and busy clinicians might find it unwieldy. However, a clinician with an individual patient could focus on only the first figure (Figure 1) plus the one other figure that addresses the specific bleeding pattern. Although we could have shortened the algorithm by using general recommendations, such as “medical therapy,” or “appropriate laboratory evaluation,” we wanted a practical tool that could stand alone at the point of care.


We sought to develop a good algorithm, but it was not clear how to define “good.” A good algo-



**Figure 6. Depo-medroxyprogesterone or Progesterone Only Pill-associated Bleeding.**

rithm might be cost-effective, evidence-based, intuitive, efficient (arrives at a treatment plan quickly without unnecessary steps), comprehensive (no

need to consult other information resources), non-invasive (avoids endometrial biopsy when possible), practice-based (works in practice), filled with ac-



**Figure 7. Intrauterine Device-associated Bleeding.**



**Table 4. Strength of Evidence for Major Management Recommendations**

Recommendation	Strength of Recommendation*
<b>TSH.</b> Obtain a thyroid-stimulating hormone (TSH) serum level in women with irregular bleeding or menorrhagia. <sup>69-73</sup>	B
<b>Age 35.</b> Obtain an endometrial biopsy in women over age 35 with irregular bleeding. <sup>2,74</sup>	B
<b>Unopposed estrogen.</b> Obtain an endometrial biopsy in women with prolonged unopposed estrogen regardless of age (most commonly, a woman with polycystic ovary syndrome (PCOS) with few or no periods for more than 2 years). <sup>2,75</sup>	C
<b>Transvaginal ultrasound.</b> Consider transvaginal ultrasound or saline-infused sonohysterogram for perimenopausal women with irregular bleeding. <sup>4,54,76</sup>	C
<b>Hormonal therapy for irregular bleeding.</b> Offer oral contraceptives or a progestin for cycle regulation in women with irregular bleeding, after ruling out structural causes, systemic causes, and contraindications to the oral contraceptive. <sup>2,8,77</sup>	B
<b>Hormonal therapy for menorrhagia.</b> Offer oral contraceptives or a progestin to decrease bleeding in women with menorrhagia after ruling out structural causes, systemic causes, and contraindications to the oral contraceptive. <sup>8,10,13,77-79</sup>	B
<b>Nonsteroidal anti-inflammatory drugs for menorrhagia.</b> Offer nonsteroidal anti-inflammatory drugs for women with menorrhagia, after ruling out structural causes and systemic causes. <sup>60,61</sup>	B

\* Strength of recommendation classified according to the 3-component SORT system<sup>80</sup>: A, recommendation based on consistent and good-quality patient-oriented evidence<sup>80</sup>; B, recommendation based on inconsistent or limited quality patient-oriented evidence<sup>80</sup>; C, recommendation based on consensus, usual practice, opinion, disease-oriented evidence, or case series for studies of diagnosis, treatment, prevention, or screening.<sup>80</sup>

tion-oriented advice (“don’t just talk *about* the problem, tell me *what to do*”), and able to account for patient preferences. A good algorithm should lead to favorable patient outcomes in a randomized clinical trial, but trials involving comprehensive algorithms for complex problems, such as abnormal uterine bleeding, are generally not feasible.

The algorithm in this study was initially based on the evidence but modified to match the actual care of patients. The strength of the evidence for the major recommendations in the algorithm are summarized Table 4. The validation procedures we followed were time consuming and may not be practical for algorithms that address other topics. However, even limited attempts to test an algorithm or compare it with actual patient care might reassure authors and readers of its usability in practice.

## Appendix

### ***Handheld Computer Version of Algorithm for the Management of Abnormal Uterine Bleeding***

#### **A. Initial approach**

1. History and physical examination
2. Rule out pregnancy
3. Determine bleeding pattern
  - a. Severe acute bleeding
  - b. Irregular bleeding
  - c. Menorrhagia

d. Contraceptive method (oral contraceptive pill (OCP), depo-medroxyprogesterone, IUD)

#### **B. Severe acute bleeding (not pregnant)**

1. Orthostatic hypotension or hemoglobin <10 g/dL or profuse bleeding. Admit to the hospital. Premarin 25 mg IV q4 hours × 24 hours + 25 mg of promethazine PO or IM or per rectum every 4 to 6 hours as needed for nausea. Dilation and curettage (D&C) if no response after 1 to 2 doses of Premarin. Transfuse if hemoglobin <7.5 g/dL. Simultaneous with IV Premarin, start LoOvral, 1 active pill QID × 4d, TID × 3d, BID × 2d, QD × 3 weeks, then one week off, then cycle for at least 3 months. If OCP contraindicated, cycle 10 mg of Provera for 14 days, off 14 days, on 14 days, and so on for at least 3 months. Obtain TVUS, TSH, complete blood cell count (CBC), platelet count, prothrombin time, activated partial thromboplastin time, and platelet function analysis. Start oral iron.
2. No orthostatic hypotension, hemoglobin ≥10 g/dL, bleeding not profuse. Outpatient management: 2.5 mg of Premarin PO QID plus 25 mg of promethazine PO or IM or per rectum every 4 to 6 hours as needed for

nausea. D&C if no response after 2 to 4 doses of Premarin or sooner if bleeding >1 pad/hour. After acute bleeding start LoOval, 1 active pill QID  $\times$  4d, TID  $\times$  3d, BID  $\times$  2d, QD  $\times$  3 weeks, then 1 week off, then cycle for at least 3 months. If OCP contraindicated, cycle 10 mg of Provera for 14 days, off 14 days, on 14 days, and so on for at least 3 months. Obtain TVUS, TSH, CBC, platelet count, prothrombin time, activated partial thromboplastin time, and platelet function analysis. Start oral iron.

#### C. Irregular bleeding in nonpregnant patient

1. TSH. Prolactin if oligomenorrhea.
2. If more than age 35 or prolonged unopposed estrogen, obtain endometrial biopsy and consider TVUS.
3. Consider as a cause endometritis (tender uterus), medications (phenytoin, antipsychotics, tricyclic antidepressants, corticosteroids), advanced systemic disease, or polycystic ovary syndrome.
4. If the patient does not want to achieve pregnancy, start oral contraceptive (eg, Necon 1/35) and cycle at least 3 months. If the oral contraceptive is contraindicated, start 10 mg of Provera QD for 14 days, off 14 days, on 14 days, and so on for at least 3 months. If abnormal bleeding persists, offer higher dose oral contraceptive (eg, Demulen 1/50) or higher dose Provera (20 mg, 30 mg, 40 mg, 60 mg, 80 mg). If abnormal bleeding persists, consider TVUS and endometrial biopsy.
5. Contraindications to oral contraceptives include history of thromboembolic event or stroke, estrogen-dependent tumor, active liver disease, pregnancy, hypertriglyceridemia, smoking more than 15 cigarettes per day when age is  $\geq 35$ .

#### D. Menorrhagia in nonpregnant patient

1. TSH. Hemoglobin. Consider platelet function analysis. Consider TVUS if abnormal uterus on pelvic examination.
2. Cycle oral contraceptive (eg, Necon 1/35). If oral contraceptive contraindicated, 10 mg of Provera QD  $\times$  14 days, off 14 days, on 14 days, and so on for at least 3 months. Other options include nonsteroidal antiinflammatory drugs (eg, 400 mg of ibuprofen TID for

4 days, starting day 1 of menses) or no treatment.

3. If response inadequate, obtain TVUS to identify polyps, myomas, endometrial hyperplasia, adenomyosis.

#### E. Oral contraceptive pill-associated bleeding


1. Menorrhagia. Refer to menorrhagia algorithm above.
2. Breakthrough bleeding. If breakthrough bleeding occurs during the first 3 months, encourage continued use. If breakthrough bleeding occurs after 3 months of use or patient requests intervention sooner, test for chlamydia and gonorrhea, ask about compliance, consider changing to higher estrogen pill (eg, Necon 1/35, Demulen 1/35, Demulen 1/50, LoOval). If more than age 35, obtain endometrial biopsy.
3. Amenorrhea. Rule out pregnancy. Consider higher estrogen pill (eg, Necon 1/35, Demulen 1/35, Demulen 1/50, LoOval). Or may continue same pill because endometrial hyperplasia should not develop on oral contraceptives.

#### F. Depo-medroxyprogesterone or progesterone-only pill-associated bleeding.

1. Amenorrhea. Advise that amenorrhea or scant bleeding is expected.
2. If unacceptable irregular bleeding and patient more than age 35 or otherwise at risk for endometrial carcinoma, do endometrial biopsy.
3. If less than age 35 and not otherwise at high risk for endometrial carcinoma and first 4 to 6 months of use, can encourage continued use or substitute oral contraceptive, or temporarily increase frequency of injections (eg, every 2 months).
4. If less than age 35 and not otherwise at high risk for endometrial carcinoma and after first 4 to 6 months of use, offer 1.25 mg of Premarin QD for 7 days. Can repeat Premarin course if abnormal bleeding recurs. Consider other methods of contraception if bleeding persists.

#### G. IUD-associated bleeding

1. Uterus tender; 100 mg of doxycycline BID for 10 days. Consider removal.
2. First 4 to 6 months of use. Encourage continued use. Can offer NSAID (eg, 400 mg of



**Figure 8. Endometrial Biopsy (Pipelle aspiration).**

ibuprofen TID for 4 days, starting day 1 of menses).

- After 4 to 6 months of use, consider oral contraceptive for one cycle or, if copper IUD, 10 mg of Provera QD for 7 days. If unacceptable bleeding persists, consider removal.

#### H. Endometrial biopsy results (eg, pipelle aspiration; Figure 8).

- Polyp. Consider hysteroscopic removal or D&C or observation.
- Disordered endometrium or stromal collapse or proliferative endometrium or secretory endometrium. Return to appropriate algorithm based on bleeding pattern.
- Endometritis; 100 mg of doxycycline BID for 10 days.
- Hyperplasia without atypia. Cyclic or continuous progestin (eg, 10 mg of Provera QD for 14 days, off 14 days, on 14 days, and so on). Repeat biopsy after 3 to 6 months. Refer if hyperplasia persists.
- Atypia or hyperplasia with atypia or carcinoma. Refer for further counseling and treatment.

#### References

- Nicholson WK, Ellison SA, Grason H, Powe NR. Patterns of ambulatory care use for gynecologic conditions: a national study. *Am J Obstet Gynecol* 2001;184:523–30.
- ACOG practice bulletin: management of anovulatory bleeding. *Int J Gynaecol Obstet* 2001;72:263–71.
- Albers JR, Hull SK, Wesley MA. Abnormal uterine bleeding. *Am Fam Phys* 2004;69:1915–26.
- Goldstein SR. Menorrhagia and abnormal bleeding before the menopause. *Best Pract Res Clin Obstet Gynaecol* 2004;18:59–69.
- Farrell E. Dysfunctional uterine bleeding. *Aust Fam Physician* 2004;33:906–8.
- Kilbourn CL, Richards CS. Abnormal uterine bleeding. Diagnostic considerations, management options. *Postgrad Med* 2001;109:137–8, 141–4, 147–50.
- Oriel KA, Schrager S. Abnormal uterine bleeding. *Am Fam Physician* 1999;60:1371–80; Discussion 1381–2.
- Kuppermann M, Varner RE, Summitt RL, Jr., et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. *JAMA* 2004;291:1447–55.
- Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. *Contraception* 2004;70:277–9.
- Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. *Obstet Gynecol* 2004;104(6):1314–21.
- Searle J, Grover S, Santin A, Weideman P. Randomised trial of an integrated educational strategy to reduce investigation rates in young women with dys-

- functional uterine bleeding. *Aust N Z J Obstet Gynaecol* 2002;42:395–400.
12. Kennedy AD, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. *JAMA* 2002;288:2701–8.
13. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. *Fertil Steril* 2001;76:304–9.
14. Cooper KG, Jack SA, Parkin DE, Grant AM. Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. *BJOG* 2001;108:1222–8.
15. Working Party for Guidelines for the Management of Heavy Menstrual Bleeding. An evidence-based guideline for the management of heavy menstrual bleeding. *N Z Med J* 1999;112:174–7.
16. Bongers MY, Mol BW, Brolmann HA. Current treatment of dysfunctional uterine bleeding. *Maturnitas* 2004;47:159–74.
17. Tscherne G. Menstrual irregularities. Evidence-based clinical practice. *Endocr Dev* 2004;7:129–39.
18. Buckingham K, Fawdry A, Fothergill D. Management of vaginal bleeding presenting to the accident and emergency department. *J Accid Emerg Med* 1999;16:130–5.
19. Iglesias EA, Coupey SM. Menstrual cycle abnormalities: diagnosis and management. *Adolesc Med* 1999;10:255–73.
20. Minjarez DA, Bradshaw KD. Abnormal uterine bleeding in adolescents. *Obstet Gynecol Clin North Am* 2000;27:63–78.
21. Minjarez DA. Abnormal bleeding in adolescents. *Semin Reprod Med* 2003;21:363–73.
22. Neale EJ, Chang AM. Clinical algorithms. *Med Teach* 1991;13:317–22.
23. Sadler C. Pitfalls in the use of clinical algorithms. *Ortho Clin North Am* 1986;17:545–547.
24. Fred HL. Algorithms: let's give them back. *Hosp Pract (Off Ed)* 2000;35:15–6.
25. Kassirer JP, Kopelman RI. Diagnosis and decisions by algorithms. *Hosp Pract (Off Ed)* 1990;25:23–4, 27, 31.
26. McDonald CJ, Wilson GA, McCabe GP, Jr. Physician response to computer reminders. *JAMA* 1980;244:1579–81.
27. Shoemaker WC, Corley RD, Liu M, et al. Development and testing of a decision tree for blunt trauma. *Crit Care Med* 1988;16:1199–208.
28. Wirtschafter DD, Sumners J, Jackson JR, Brooks CM, Turner M. Continuing medical education using clinical algorithms: a controlled trial assessment of effect on neonatal care. *Am J Dis Child* 1986;140:791–7.
29. Margolis CZ, Cook CD, Barak N, Adler A, Geertsma A. Clinical algorithms teach pediatric decision making more effectively than prose. *Med Care* 1989;27:576–92.
30. Margolis CZ. Pediatric algorithms. *J Pediatr* 1987;110:417–8.
31. Feinstein AR. An analysis of diagnostic reasoning: III. The construction of clinical algorithms. *Yale J Biol Med* 1974;1:5–32.
32. Horabin I, Lewis BN. Algorithms. Englewood Cliffs (NJ): Educational Technology Publications; 1978.
33. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Baltimore: Lippincott Williams & Wilkins; 2004.
34. Epstein E, Valentin L. Managing women with postmenopausal bleeding. *Best Pract Res Clin Obstet Gynaecol* 2004;18:125–43.
35. James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. *Obstet Gynecol* 2004;104:381–8.
36. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. *BJOG* 2004;111:734–40.
37. Dijkhuizen FP, Mol BW, Bongers MY, Brolmann HA, Heintz AP. Cost-effectiveness of transvaginal sonography and saline infused sonography in the evaluation of menorrhagia. *Int J Gynaecol Obstet* 2003;83:45–52.
38. Turner RT, Berman AM, Topel HC. Improved demonstration of endometrial polyps and submucous myomas using saline-enhanced vaginal sonohysterography. *J Am Assoc Gynecol Laparosc* 1995;2:421–5.
39. Mitan LA, Slap GB. Adolescent menstrual disorders. Update. *Med Clin North Am* 2000;84:851–68.
40. Strickland JL, Wall JW. Abnormal uterine bleeding in adolescents. *Obstet Gynecol Clin North Am* 2003;30:321–35.
41. Kaunitz AM. Gynecologic problems of the perimenopause: evaluation and treatment. *Obstet Gynecol Clin North Am* 2002;29:455–73.
42. Weiss G. Menstrual irregularities and the perimenopause. *J Soc Gynecol Investig* 2001;8(1 Suppl Proceedings):S65–6.
43. Field CS. Dysfunctional uterine bleeding. *Prim Care* 1988;15:561–74.
44. Crosignani PG, Vegetti W. A practical guide to the diagnosis and management of amenorrhoea. *Drugs* 1996;52:671–81.
45. Wathen PI, Henderson MC, Witz CA. Abnormal uterine bleeding. *Med Clin North Am* 1995;79:329–44.
46. Chen KT. Acute and chronic endometritis. Available from: UpToDate.com. Accessed on March 25, 2006.
47. Michels TC. Chronic endometritis. *Am Fam Physician* 1995;52:217–22.
48. Brenner PF. Differential diagnosis of abnormal uterine bleeding. *Am J Obstet Gynecol* 1996;175(3 Pt 2):766–9.



49. Gordon CM. Menstrual disorders in adolescents. Excess androgens and the polycystic ovary syndrome. *Pediatr Clin North Am* 1999;46:519–43.
50. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004;19:41–7.
51. Barbieri RL, Ehrmann DA. Diagnosis and treatment of polycystic ovary syndrome in adults. Available from: UpToDate.com. Accessed on March 25, 2006.
52. Kelekci S, Kaya E, Alan M, Alan Y, Bilge U, Molamahmutoglu L. Comparison of transvaginal sonography, saline infusion sonography, and office hysteroscopy in reproductive-aged women with or without abnormal uterine bleeding. *Fertil Steril* 2005;84:682–6.
53. Valenzano MM, Lijoi D, Mistrangelo E, Fortunato T, Costantini S, Ragni N. The value of sonohysterography in detecting intracavitary benign abnormalities. *Arch Gynecol Obstet* 2005;272:265–8. Epub 2005 Oct 13.
54. Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. *Am J Obstet Gynecol* 1997;177:102–8.
55. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. *Am J Obstet Gynecol* 2004;190:1216–23.
56. Kouides PA, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. *Fertil Steril* 2005;84:1345–51.
57. Kujovich JL. von Willebrand's disease and menorrhagia: prevalence, diagnosis, and management. *Am J Hematol* 2005;79:220–8.
58. Philipp CS, Miller CH, Faiz A, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. *Haemophilia* 2005;11:497–503.
59. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. *JAMA* 2004;291:1456–63.
60. Grover V, Usha R, Gupta U, Kalra S. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. *Asia Oceania J Obstet Gynaecol* 1990;16:255–9.
61. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. *Aust N Z J Obstet Gynaecol* 1991;31:66–70.
62. Rosenfeld JA. Treatment of menorrhagia due to dysfunctional uterine bleeding. *Am Fam Physician* 1996;53:165–72.
63. Rees M. Menorrhagia. *Br Med J (Clin Res Ed)* 1987;294:759–62.
64. Bulusu S. Secondary amenorrhoea. *J R Soc Med* 1996;89:220P–1P.
65. Aloï JA. Evaluation of amenorrhea. *Compr Ther* 1995;21:575–8.
66. Burnett RG. Diagnostic strategies for amenorrhea. *Postgrad Med* 1990;87:241–7, 250.
67. Franks S. Primary and secondary amenorrhoea. *Br Med J (Clin Res Ed)* 1987;294:815–9.
68. Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. *JAMA* 1993;269:1823–8.
69. Rowland AS, Baird DD, Long S, et al. Influence of medical conditions and lifestyle factors on the menstrual cycle. *Epidemiology* 2002;13:668–74.
70. Weeks AD. Menorrhagia and hypothyroidism. Evidence supports association between hypothyroidism and menorrhagia. *BMJ* 2000;320:649.
71. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. *Clin Endocrinol (Oxf)* 1999;50:655–9.
72. Koutras DA. Disturbances of menstruation in thyroid disease. *Ann N Y Acad Sci* 1997;816:280–4.
73. Krassas GE, Pontikides N, Kaltsas T, Papadopoulou P, Batrinos M. Menstrual disturbances in thyrotoxicosis. *Clin Endocrinol (Oxf)* 1994;40:641–4.
74. SEER data Available from: <http://seer.cancer.gov/faststats/sites.php?stat=Incidence&site=Corpus+and+Uterus%2C+NOS+Cancer&x=13&y=16>. Accessed on April 15, 2006.
75. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. *Obstet Gynecol* 1986;68:741–5.
76. Dubinsky TJ. Value of sonography in the diagnosis of abnormal vaginal bleeding. *J Clin Ultrasound* 2004;32:348–53.
77. Learman LA, Summitt RL Jr., Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. *Obstet Gynecol* 2004;103(5 Pt 1):824–33.
78. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. *JAMA* 2004;291:1456–63.
79. Lahteenmaki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. *BMJ* 1998;316:1122–6.
80. Ebell MH, Siwek J, Weiss BD. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *J Fam Pract* 2004;53:111–20.